EW
Edwards Lifesciences Corporation NYSE Listed Mar 27, 2000$82.75
Mkt Cap $47.7B
52w Low $72.30
67.0% of range
52w High $87.89
50d MA $82.23
200d MA $81.16
P/E (TTM)
45.6x
EV/EBITDA
33.3x
P/B
4.8x
Debt/Equity
0.1x
ROE
10.4%
P/FCF
37.3x
RSI (14)
—
ATR (14)
—
Beta
0.94
50d MA
$82.23
200d MA
$81.16
Avg Volume
5.2M
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
One Edwards Way · Irvine, CA 92614 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | AMC | 0.73 | 0.78 | +7.0% | 79.72 | +3.5% | +5.6% | -0.8% | -1.4% | -1.3% | +2.8% | — |
| Feb 10, 2026 | AMC | 0.62 | 0.58 | -6.1% | 77.05 | +2.0% | +3.0% | -3.6% | -0.7% | +3.4% | +0.7% | — |
| Oct 30, 2025 | AMC | 0.60 | 0.67 | +12.4% | 83.48 | +1.2% | -1.2% | +0.8% | +1.3% | -1.6% | -0.5% | — |
| Jul 24, 2025 | AMC | 0.62 | 0.67 | +7.4% | 75.80 | +7.5% | +5.5% | -1.9% | +2.5% | +0.9% | -2.3% | — |
| Apr 23, 2025 | AMC | 0.60 | 0.64 | +7.4% | 70.46 | +5.3% | +6.6% | +1.2% | -0.7% | +1.0% | -1.0% | — |
| Feb 11, 2025 | AMC | 0.55 | 0.59 | +7.1% | 70.91 | +4.4% | +6.9% | +0.2% | +0.3% | -0.7% | -1.3% | — |
| Oct 24, 2024 | AMC | 0.67 | 0.67 | +0.8% | 70.35 | -2.1% | -1.4% | -1.2% | +1.2% | -1.1% | -2.4% | — |
| Jul 24, 2024 | AMC | 0.69 | 0.70 | +1.4% | 86.95 | -26.4% | -31.3% | +4.5% | +2.2% | -0.2% | -0.9% | — |
| Apr 25, 2024 | AMC | 0.64 | 0.66 | +3.1% | 88.01 | -1.1% | -1.8% | -0.6% | -1.5% | -0.4% | +0.9% | — |
| Feb 6, 2024 | AMC | 0.64 | 0.64 | +0.0% | 88.25 | +1.3% | -1.9% | -0.9% | -0.9% | +2.5% | -1.0% | — |
| Oct 25, 2023 | AMC | 0.59 | 0.59 | +0.0% | 68.34 | -8.5% | -8.1% | -1.7% | +1.1% | +2.2% | +0.2% | — |
| Jul 26, 2023 | AMC | 0.65 | 0.66 | +1.5% | 91.63 | -5.1% | -9.8% | +1.3% | -2.0% | -0.0% | -2.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | Barclays | Maintains | Overweight → Overweight | — | $84.15 | $83.54 | -0.7% | -0.8% | -1.4% | -1.3% | +2.8% | +0.6% |
| Apr 24 | Truist | Maintains | Hold → Hold | — | $79.72 | $82.50 | +3.5% | +5.6% | -0.8% | -1.4% | -1.3% | +2.8% |
| Apr 24 | Evercore ISI | Maintains | Outperform → Outperform | — | $79.72 | $82.50 | +3.5% | +5.6% | -0.8% | -1.4% | -1.3% | +2.8% |
| Apr 24 | Baird | Maintains | Neutral → Neutral | — | $79.72 | $82.50 | +3.5% | +5.6% | -0.8% | -1.4% | -1.3% | +2.8% |
| Apr 24 | BTIG | Maintains | Buy → Buy | — | $79.72 | $82.50 | +3.5% | +5.6% | -0.8% | -1.4% | -1.3% | +2.8% |
| Apr 24 | Canaccord Genuity | Maintains | Hold → Hold | — | $79.72 | $82.50 | +3.5% | +5.6% | -0.8% | -1.4% | -1.3% | +2.8% |
| Apr 13 | Mizuho | Maintains | Outperform → Outperform | — | $77.87 | $77.57 | -0.4% | +0.3% | +0.1% | +0.0% | +1.1% | +2.5% |
| Apr 6 | Evercore ISI | Maintains | Outperform → Outperform | — | $81.05 | $81.00 | -0.1% | +0.2% | -0.4% | +1.1% | -3.1% | -1.6% |
| Feb 11 | BTIG | Maintains | Buy → Buy | — | $77.05 | $78.61 | +2.0% | +3.0% | -3.6% | -0.7% | +3.4% | +0.7% |
| Feb 11 | Goldman Sachs | Maintains | Buy → Buy | — | $77.05 | $78.61 | +2.0% | +3.0% | -3.6% | -0.7% | +3.4% | +0.7% |
| Feb 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $77.05 | $78.61 | +2.0% | +3.0% | -3.6% | -0.7% | +3.4% | +0.7% |
| Feb 11 | Truist | Maintains | Hold → Hold | — | $77.05 | $78.61 | +2.0% | +3.0% | -3.6% | -0.7% | +3.4% | +0.7% |
| Feb 11 | Wells Fargo | Maintains | Overweight → Overweight | — | $77.05 | $78.61 | +2.0% | +3.0% | -3.6% | -0.7% | +3.4% | +0.7% |
| Jan 20 | Piper Sandler | Maintains | Overweight → Overweight | — | $84.35 | $83.73 | -0.7% | -1.1% | +2.0% | -0.8% | -0.9% | +0.7% |
| Jan 20 | Stifel | Maintains | Buy → Buy | — | $84.35 | $83.73 | -0.7% | -1.1% | +2.0% | -0.8% | -0.9% | +0.7% |
| Jan 12 | Barclays | Maintains | Overweight → Overweight | — | $85.13 | $86.00 | +1.0% | -2.5% | +1.0% | -0.9% | +1.7% | -0.2% |
| Jan 12 | UBS | Maintains | Neutral → Neutral | — | $85.13 | $86.00 | +1.0% | -2.5% | +1.0% | -0.9% | +1.7% | -0.2% |
| Jan 9 | TD Cowen | Upgrade | Hold → Buy | — | $84.58 | $85.28 | +0.8% | +0.7% | -2.5% | +1.0% | -0.9% | +1.7% |
| Jan 7 | Stifel | Maintains | Buy → Buy | — | $85.85 | $86.27 | +0.5% | -1.2% | -0.3% | +0.7% | -2.5% | +1.0% |
| Dec 18 | JP Morgan | Upgrade | Neutral → Overweight | — | $84.84 | $85.83 | +1.2% | -0.0% | +1.0% | +1.0% | -0.3% | +0.1% |
| Dec 17 | Canaccord Genuity | Maintains | Hold → Hold | — | $85.32 | $85.76 | +0.5% | -0.6% | -0.0% | +1.0% | +1.0% | -0.3% |
| Dec 16 | Baird | Maintains | Neutral → Neutral | — | $83.38 | $83.16 | -0.3% | +2.3% | -0.6% | -0.0% | +1.0% | +1.0% |
| Dec 11 | Citigroup | Maintains | Buy → Buy | — | $83.92 | $84.35 | +0.5% | +0.4% | -1.4% | +0.4% | +2.3% | -0.6% |
| Dec 8 | Barclays | Maintains | Overweight → Overweight | — | $86.19 | $86.01 | -0.2% | -2.2% | -1.2% | +0.8% | +0.4% | -1.4% |
| Dec 5 | UBS | Maintains | Neutral → Neutral | — | $85.78 | $86.31 | +0.6% | +0.5% | -2.2% | -1.2% | +0.8% | +0.4% |
| Dec 5 | Wells Fargo | Maintains | Overweight → Overweight | — | $85.78 | $86.31 | +0.6% | +0.5% | -2.2% | -1.2% | +0.8% | +0.4% |
| Dec 5 | RBC Capital | Maintains | Outperform → Outperform | — | $85.78 | $86.31 | +0.6% | +0.5% | -2.2% | -1.2% | +0.8% | +0.4% |
| Dec 5 | BTIG | Maintains | Buy → Buy | — | $85.78 | $86.31 | +0.6% | +0.5% | -2.2% | -1.2% | +0.8% | +0.4% |
| Dec 5 | Baird | Maintains | Neutral → Neutral | — | $85.78 | $86.31 | +0.6% | +0.5% | -2.2% | -1.2% | +0.8% | +0.4% |
| Dec 5 | Truist | Maintains | Hold → Hold | — | $85.78 | $86.31 | +0.6% | +0.5% | -2.2% | -1.2% | +0.8% | +0.4% |
| Dec 5 | Stifel | Maintains | Buy → Buy | — | $85.78 | $86.31 | +0.6% | +0.5% | -2.2% | -1.2% | +0.8% | +0.4% |
| Dec 5 | Canaccord Genuity | Maintains | Hold → Hold | — | $85.78 | $86.31 | +0.6% | +0.5% | -2.2% | -1.2% | +0.8% | +0.4% |
| Nov 25 | BTIG | Maintains | Buy → Buy | — | $84.71 | $84.66 | -0.1% | +2.5% | -0.1% | -0.1% | -1.6% | -0.7% |
| Nov 3 | Canaccord Genuity | Maintains | Hold → Hold | — | $82.45 | $83.41 | +1.2% | +0.8% | +1.3% | -1.6% | -0.5% | +1.2% |
| Nov 3 | Truist | Maintains | Hold → Hold | — | $82.45 | $83.41 | +1.2% | +0.8% | +1.3% | -1.6% | -0.5% | +1.2% |
| Oct 31 | Goldman Sachs | Maintains | Buy → Buy | — | $83.48 | $84.48 | +1.2% | -1.2% | +0.8% | +1.3% | -1.6% | -0.5% |
| Oct 31 | Piper Sandler | Maintains | Overweight → Overweight | — | $83.48 | $84.48 | +1.2% | -1.2% | +0.8% | +1.3% | -1.6% | -0.5% |
| Oct 31 | Stifel | Maintains | Buy → Buy | — | $83.48 | $84.48 | +1.2% | -1.2% | +0.8% | +1.3% | -1.6% | -0.5% |
| Oct 31 | Citigroup | Maintains | Buy → Buy | — | $83.48 | $84.48 | +1.2% | -1.2% | +0.8% | +1.3% | -1.6% | -0.5% |
| Oct 31 | Barclays | Maintains | Overweight → Overweight | — | $83.48 | $84.48 | +1.2% | -1.2% | +0.8% | +1.3% | -1.6% | -0.5% |
| Oct 31 | RBC Capital | Maintains | Outperform → Outperform | — | $83.48 | $84.48 | +1.2% | -1.2% | +0.8% | +1.3% | -1.6% | -0.5% |
| Oct 31 | Evercore ISI | Maintains | Outperform → Outperform | — | $83.48 | $84.48 | +1.2% | -1.2% | +0.8% | +1.3% | -1.6% | -0.5% |
| Oct 31 | Mizuho | Maintains | Outperform → Outperform | — | $83.48 | $84.48 | +1.2% | -1.2% | +0.8% | +1.3% | -1.6% | -0.5% |
| Oct 31 | JP Morgan | Maintains | Neutral → Neutral | — | $83.48 | $84.48 | +1.2% | -1.2% | +0.8% | +1.3% | -1.6% | -0.5% |
| Oct 29 | Wolfe Research | Upgrade | Underperform → Peer Perform | — | $82.19 | $84.50 | +2.8% | +0.6% | +1.0% | -1.2% | +0.8% | +1.3% |
| Oct 29 | Jefferies | Upgrade | Hold → Buy | — | $82.19 | $84.50 | +2.8% | +0.6% | +1.0% | -1.2% | +0.8% | +1.3% |
| Oct 28 | Truist | Maintains | Hold → Hold | — | $80.82 | $80.17 | -0.8% | +1.7% | +0.6% | +1.0% | -1.2% | +0.8% |
| Oct 8 | Oppenheimer | Downgrade | Outperform → Perform | — | $76.72 | $74.50 | -2.9% | -1.3% | -0.7% | -1.7% | -1.3% | +0.6% |
| Oct 7 | Evercore ISI | Upgrade | In Line → Outperform | — | $76.56 | $77.85 | +1.7% | +0.2% | -1.3% | -0.7% | -1.7% | -1.3% |
| Sep 22 | Stifel | Maintains | Buy → Buy | — | $74.41 | $74.20 | -0.3% | -0.9% | +1.1% | +0.1% | +0.8% | +1.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | Lippis Daniel J.Off | CVP, TAVR | Sell | 1,019 | $83.98 | $86K | 33,681 | -0.50% | — |
| May 1, 2026 | Lippis Daniel J.Off | CVP, TAVR | Sell | 1,000 | $82.99 | $83K | 33,933 | -0.50% | — |
| May 1, 2026 | Lippis Daniel J.Off | CVP, TAVR | Sell | 19 | $83.99 | $2K | 34,933 | -0.50% | — |
8-K
Edwards Lifesciences Corp -- 8-K Filing
Edwards Lifesciences reported Q1 2026 results, with CEO Bernard Zovighian reaffirming the company's strategic focus on structural heart disease innovation and addressing complex patient needs.
Apr 23
8-K
Edwards Lifesciences Corp -- 8-K Filing
Edwards Lifesciences reported strong fourth-quarter results and raised its 2026 outlook, citing confidence in sustained growth from its valve innovation expertise and clinical evidence.
Feb 10
Data updated apr 25, 2026 8:05am
· Source: massive.com